Hormonal
Long-acting GLP-1 receptor agonists (dulaglutide, liraglutide, once-weekly exenatide) provide superior glycemic control (HbA1c and FPG reduction) compared to short-acting agents (EBID, lixisenatide) in type 2 diabetes patients.
If you have Type 2 Diabetes and need better blood sugar control, long-acting GLP-1 medications (like dulaglutide, liraglutide, or once-weekly exenatide) are more effective at lowering HbA1c and fasting glucose than short-acting versions (like twice-daily exenatide or lixisenatide). Choose a long-acting option for superior glycemic results, keeping in mind that all GLP-1s carry a risk of gastrointestinal side effects.
dulaglutide, liraglutide, and once-weekly exenatide are superior to EBID and lixisenatide at lowering HbA1c and FPG.
Why this rating
Based on a systematic review and mixed-treatment comparison meta-analysis of 34 RCTs involving 14,464 participants.
Source
Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: <scp>A</scp> systematic review and mixed‐treatment comparison analysis
Zin Zin Htike et al. · Diabetes Obesity and Metabolism · 2016
DOI 10.1111/dom.12849
More from this paper
- Among long-acting GLP-1 receptor agonists, once-weekly exenatide is associated with the lowest risk of vomiting compared to other agents in the class.Strong
- Long-acting GLP-1 receptor agonists (dulaglutide, liraglutide, once-weekly exenatide) are associated with greater weight loss compared to short-acting agents (EBID, lixisenatide) when directly compared, although differences among long-acting agents are not clinically meaningful.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →